Silverback Therapeutics, Inc.$5.87 %
Analyst Rating: Hold
Stock Details
CEO
Peter A. Thompson
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
90
Address
500 Fairview Avenue North, Seattle, WA, 98109
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Top Competitors
Income Statement
Financials
Selected Year
Revenue Estimates
EPS Estimates
Net Income Estimates
Price target for Silverback Therapeutics, Inc. $5.87
$0
Min Forecast(+0% )
$249.61
Avg Forecast( +0% )
$325
Max Forecast(+0%)
EPS
Revenue
Institutional Holder
Loading institutional holder data...
Congress Tracker
Showing 0 of 0 results
Insider Trading of Key Employees
Showing 0 of 0 results